抗菌药物在肝硬化患者中的应用

韩丹; 祁兴顺; 郭晓钟

doi:10.3969/j.issn.1001-5256.2017.03.038

抗菌药物在肝硬化患者中的应用

DOI: 10.3969/j.issn.1001-5256.2017.03.038

1. 辽宁中医药大学研究生院
2. 中国人民解放军沈阳军区总院消化内科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2044
- HTML全文浏览量: 35
- PDF下载量: 517
- 被引次数: 0
出版历程
- 收稿日期: 2016-10-20
- 出版日期: 2017-03-20

Application of antibacterial agents in patients with liver cirrhosis

Graduate School of Liaoning University of Traditional Chinese Medicine

摘要

摘要: 肝硬化患者常伴有细菌感染,最常见的细菌感染类型为自发性细菌性腹膜炎。临床上,抗菌药物广泛用于自发性细菌性腹膜炎的防治。此外,抗菌药物也可降低肝硬化上消化道出血患者的再出血率及病死率。然而,为避免细菌耐药,合理应用抗菌药物是必要的。综述了抗菌药物在肝硬化患者中的主要适应证和耐药情况。
- 肝硬化 /
- 抗菌药 /
- 综述
Abstract: Bacterial infection is frequently seen in patients with liver cirrhosis, and the most common type of bacterial infection is spontaneous bacterial peritonitis (SBP) .In clinical practice, antibacterial agents are widely used in the treatment of SBP.In addition, antibacterial agents can reduce rebleeding and mortality rates in patients with upper gastrointestinal bleeding.However, in order to avoid bacterial resistance, the appropriate use of antibacterial agents is very important.This article reviews the indications and resistance of antibacterial agents in patients with liver cirrhosis.
- liver cirrhosis /
- anti-bacterial agents /
- review

HTML全文

参考文献(36)

[1]ARVANITI V, D'AMICO G, FEDE G, et al.Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J].Gastroenterology, 2010, 139 (4) :1246-1256.

[2]BUNCHORNTAVAKUL C, CHAMROONKUL N, CHAVALITDHAM-RONG D.Bacterial infections in cirrhosis:a critical review and practical guidance[J].World J Hepatol, 2016, 8 (6) :307.

[3]STEIB CJ, SCHEWE J, GERBES AL.Infection as a trigger for portal hypertension[J].Dig Dis, 2015, 33 (4) :570-576.

[4]LU L.Risk factors of liver cirrhosis ascites complicated with spontaneous bacterial peritonitis[J].China Med Herald, 2016, 13 (8) :140-142. (in Chinese) 陆琳.肝硬化腹水并发自发性细菌性腹膜炎的危险因素[J].中国医药导报, 2016, 13 (8) :140-142.

[5]DEVER JB, SHEIKH MY.Review article:spontaneous bacterial peritonitis-bacteriology, diagnosis, treatment, risk factors and prevention[J].Aliment Pharmacol Ther, 2015, 41 (11) :1116-1131.

[6]WU HQ, WANG H.Diagnosis and treatment of spontaneous bacterial peritonitis in patients with liver ascites[J].J Clin Hepatol, 2012, 28 (9) :651-653. (in Chinese) 吴海清, 王晖.肝硬化腹水伴自发性细菌性腹膜炎的诊断及治疗[J].临床肝胆病杂志, 2012, 28 (9) :651-653.

[7]SONG YY, JIANG YY.Research advances in diagnosis and treatment of spontaneous bacterial peritonitis[J].J Clin Hepatol, 2016, 32 (6) :1188-1191. (in Chinese) 宋媛媛, 江宇泳.自发性细菌性腹膜炎诊断与治疗的研究进展[J].临床肝胆病杂志, 2016, 32 (6) :1188-1191.

[8]AHGELI P, GUARDA S, FASOLATO S, et al.Switch therapy with ciprofloxacin vs.intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis:similar efficacy at lower cost[J].Aliment Pharmacol Ther, 2006, 23 (1) :75-84.

[9]LIAO XH.Management of spontaneous bacterial peritonitis in patients with liver cirrhosis[J].J Clin Hepatol, 2011, 27 (10) :1015-1018. (in Chinese) 缪晓辉.肝硬化合并自发性细菌性腹膜炎的处理[J].临床肝胆病杂志, 2011, 27 (10) :1015-1018.

[10]PIANO S, FASOLATO S, SALINAS F, et al.The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis:results of a randomized, controlled clinical trial[J].Hepatology, 2016, 63 (4) :1299-1309.

[11]JINDAL A, KUMAR M, BHADORIA AS, et al.A randomized open label study of‘imipenem vs.cefepime’in spontaneous bacterial peritonitis[J].Liver Int, 2016, 36 (5) :677-687.

[12]SAAB S, HERNANDEZ JC, CHI AC, et al.Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis:a meta-analysis[J].Am J Gastroenterol, 2009, 104 (4) :993-1001, 1002.

[13]LOOMBA R, WESLEY R, BAIN A, et al.Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis:meta-analysis[J].Clin Gastroenterol Hepatol, 2009, 7 (4) :487-493.

[14]FERNANDEZ J, NAVASA M, PLANAS R, et al.Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis[J].Gastroenterology, 2007, 133 (3) :818-824.

[15]TERG R, FASSIO E, GUEVARA M, et al.Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis:a randomized, placebo-controlled study[J].J Hepatol, 2008, 48 (5) :774-779.

[16]HANOUNEH MA, HANOUNEH IA, HASHASH JG, et al.The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis[J].J Clin Gastroenterol, 2012, 46 (8) :709-715.

[17]AAAEM M, ELSABAAWY M, ABDELRASHED M, et al.Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites:a prospective randomized open-label comparative multicenter study[J].Hepatol Int, 2016, 10 (2) :377-385.

[18]GINES P, RIMOLA A, PLANAS R, et al.Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis:results of a double-blind, placebo-controlled trial[J].Hepatology, 1990, 12 (4 Pt 1) :716-724.

[19]BAUER TM, FOLLO A, NAVASA M, et al.Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence[J].Dig Dis Sci, 2002, 47 (6) :1356-1361.

[20]ELFERT A, ABO AL, SOLIMAN S, et al.Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis[J].Eur J Gastroenterol Hepatol, 2016, 28 (12) :1450-1454.

[21]LEE YY.Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding[J].World J Gastroenterol, 2014, 20 (7) :1790.

[22]JALAN R, FERNANDEZ J, WIEST R, et al.Bacterial infections in cirrhosis:a position statement based on the EASL Special Conference 2013[J].J Hepatol, 2014, 60 (6) :1310-1324.

[23]HONG SN, KIM BJ, LEE SY, et al.Prospective randomized trial of intravenous ciprofloxacin for prevention of bacterial infection in cirrhotic patients with esophageal variceal bleeding[J].Taehan Kan Hakhoe Chi, 2002, 8 (3) :288-296.

[24]LIN YT, LO GH, LAI KH, et al.Prophylactic antibiotics in cirrhotics with upper gastrointestinal hemorrhage:a prospective, controlled trial[J].Chin Med J:Taibei, 2002, 65 (8) :365-371.

[25]HOU MC, LIN HC, LIU TT, et al.Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage:a randomized trial[J].Hepatology, 2004, 39 (3) :746-753.

[26]XU HW, WANG JH, TSAI MS, et al.The effects of cefazolin on cirrhotic patients with acute variceal hemorrhage after endoscopic interventions[J].Surg Endosc, 2011, 25 (9) :2911-2918.

[27]FERNNDEZ J, RUIZ del AL, GMEZ C, et al.Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage[J].Gastroenterology, 2006, 131 (4) :1049-1056, 1285.

[28]DIAZ FJ, ROMAN R, BUSTIOS C, et al.Ciprofloxacin vs cefazolin in the prevention of infection in cirrhotic patients with gastrointestinal bleeding[J].Rev Gastroenterol Peru, 2011, 31 (4) :319-323.

[29]WU CK, WANG JH, LEE CH, et al.The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at differen clinical stages of disease after endoscopic interventions for acute variceal hemorrhage[J].PLoS One, 2013, 8 (4) :e61666.

[30]BERNARD B, GRANGE JD, KHAC EN, et al.Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding:a meta-analysis[J].Hepatology, 1999, 29 (6) :1655-1661.

[31]PENG Y, QI XS, GUO XZ.Report of the Baveno VI Consensus Workshop:stratifying risk and individualizing care for portal hypertension[J].J Clin Hepatol, 2015, 31 (8) :1202-1207. (in Chinese) 彭颖, 祁兴顺, 郭晓钟.2015年BavenoⅥ共识:门静脉高压的风险分层及个体化管理[J].临床肝胆病杂志, 2015, 31 (8) :1202-1207.

[32]DENG H, QI XS, GUO XZ.UK guidelines on the management o variceal haemorrhage in cirrhosis patients (2015) :an excerpt o recommendations[J].J Clin Hepatol, 2015, 31 (6) :852-854. (in Chinese) 邓晗, 祁兴顺, 郭晓钟.《2015年英国肝硬化静脉曲张出血防治指南》摘译[J].临床肝胆病杂志, 2015, 31 (6) :852-854.

[33]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Endoscopy, Chinese Medical Asscciation.Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic protal hypertension[J].J Clin Hepatol, 2016, 32 (2) :203-219. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J].临床肝胆病杂志, 2016, 32 (2) :203-219.

[34]FERNANDEZ J, TANDON P, MENSA J, et al.Antibiotic prophylaxis in cirrhosis:good and bad[J].Hepatology, 2016, 63 (6) :2019-2031.

[35]FERNANDEZ J, ACEVEDO J, CASTRO M, et al.Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis:a prospective study[J].Hepatology, 2012, 55 (5) :1551-1561.

[36]de MATTOS AA, COSTABEBER AM, LIONCO LC, et al.Multi-resistant bacteria in spontaneous bacterial peritonitis:a new step in management?[J].World J Gastroenterol, 2014, 20 (39) :14079-14086.

施引文献

资源附件(0)

访问统计